Patient discusses immunotherapy test results with an oncology clinician in a consultation room

Blood vs Tissue TMB: What Immunotherapy Tests Really Show

A guide to reading TMB reports and organizing questions for an oncology visit.

Illustration note: The opening scene is editorial illustration, not a documented consultation, study participant or test result.

Use this guide as a reading aid before discussing a TMB report. Start with the question being asked rather than a screenshot of a number.

What does tumor mutational burden measure?

Tumor mutational burden, or TMB, reports qualifying mutations per megabase of DNA examined. The sample and analysis determine what enters that estimate.

Source Question it addresses Boundary
February 2020 pilot Technical tissue/plasma comparison Four cases, not a treatment-selection trial
June 2020 FDA notice Defined pembrolizumab indication Not every assay or treatment setting
2026 meeting abstract Retrospective treatment-outcome association Not randomized test-guided care

Check each source’s question and design before combining conclusions.

What does the FDA’s TMB-high approval actually cover?

The FDA’s June 16, 2020 accelerated approval covered pembrolizumab for adult and pediatric patients with unresectable or metastatic TMB-high solid tumors, measured by an FDA-approved test at 10 or more mutations/Mb. It required progression after prior treatment and no satisfactory alternatives.

The notice named FoundationOneCDx as a companion diagnostic. Its supporting analysis included 102 TMB-high patients, with a 29% response rate and 95% confidence interval of 21% to 39%.

Response was not a promise of cure, and the notice describes serious immune-mediated risks. This dated approval does not establish eligibility from an arbitrary laboratory number.

The notice also states that safety and effectiveness in pediatric TMB-high central nervous system cancers were not established.

Why can blood and tissue TMB disagree?

Friedlaender’s February 2020 pilot compared tissue and plasma in four consecutive metastatic non-small cell lung cancer patients starting pembrolizumab. Low tumor-DNA fractions and filtering complicated comparisons; plasma values were not always higher.

The pilot predates the FDA notice. Four cases cannot establish a conversion factor or benefit from test-guided treatment.

For a different testing question, our guide to urine cancer tests separates bladder and ovarian contexts. Its conclusions should not be imported as TMB rules.

What did the 2026 paired-sample analysis find?

The 2026 retrospective abstract covered 221 paired-test patients from July 2021 to July 2025. Its treatment-outcome analysis included 80 immune-checkpoint-inhibitor recipients.

The median blood-to-tissue TMB ratio across paired samples was 2.3. At blood cutoff 16 mut/Mb, time-to-treatment-failure medians were 21.3 months (high tissue/low blood, n=4) and 7.0 months (low tissue/high blood, n=16).

Raising the blood threshold from 10 to 16 changed the low-tissue/high-blood group from 32 to 16 people. Its changed median was not a benefit caused by moving a cutoff.

What can this analysis not establish?

Time to treatment failure is not overall survival. These nonrandomized medians are not individual forecasts or conversion factors.

Separate three questions in a claim: what was measured, what happened afterward and whether using that measurement improved care. Do not fill an unanswered question with a result from another evidence category.

Where does TMB fit in a care discussion?

Keep the conversation specific to the decision being discussed. Ask your oncology team which other findings matter and what information is still missing.

The note below is an optional organizing aid, not an eligibility checklist or medical score. It contains no cutoff that tells a reader to accept, decline or change treatment.

Questions to take to your oncology appointment

Record Report A Report B
Collection date and sample Copy what is stated Copy what is stated
Assay name and reported units Copy what is stated Copy what is stated
Question for the care team Which decision is each report intended to inform, and what cannot be compared directly?

Leave an unstated field marked “not stated.” Bring the complete reports and ask the team to explain the missing context rather than calculating a replacement result.

You can also ask what an inconclusive result would change and whether more information would alter the plan. This article cannot decide whether another sample or test is appropriate.

The bottom line

Bring the note to your appointment and identify the question you want answered. Keep any missing information visible.

A number alone is not a care plan. Treatment decisions belong with the oncology team reviewing the complete clinical picture.

References

Friedlaender, A., et al. (2020). Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors. Frontiers in Oncology, 10, 142.

U.S. Food and Drug Administration. (2020, June 16). FDA approves pembrolizumab for adults and children with TMB-H solid tumors.

VanDommelen, K., & Kamath, S. D. (2026). Real-world concordance of tumor mutational burden (TMB) between blood (circulating tumor DNA) and tissue, and its association with immunotherapy response [Meeting abstract 2580]. Journal of Clinical Oncology, 44(16_suppl). DOI.

Medical disclaimer: This article provides general health information, not medical advice. Do not start, stop or change cancer treatment based on a TMB number or this article.

Review your complete test report and options with your oncology care team.

Share your love
Chris Pruitt, certified personal trainer and WorkoutHealthy founder
Chris Pruitt

Chris Pruitt is a certified ASFA personal trainer and the founder of WorkoutHealthy, a fitness equipment retailer serving customers since 2007. He has more than 16 years in the fitness business, and he writes and fact checks everything published on Insider.

The Insider Five

Five stories worth your time, every Friday. One email a week, no pitches.